News

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals (NASDAQ:ALNY) announced Tuesday partnerships with Viz.ai and the American Heart Association aimed at improving early…

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a…

New AI Care Pathway combines AI echocardiography analysis with coordinated, guideline-based next steps for cardiology and heart failure teamsSAN FRANCISCO, CA –…

AL amyloidosis is when abnormal proteins called light chains collect in organs. UCSF is studying a drug for people with relapsed or refractory multiple myeloma or…

a study on AL AmyloidosisAmyloidosisOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120…

A 53-year-old male patient, previously diagnosed with genetic amyloidosis at Hanoi French Hospital in 2024, has successfully undergone a combined heart and liver…

Start dateThu, 03/19/2026 - 12:00End dateThu, 03/19/2026 - 12:00Venue - Full AddressKeble CollegeParks RoadOxfordOX1 3PGOrganiserBritish Society of Cardiovascular…

Amyloidosis is a group of protein-folding disorders characterized by the infiltration of multiple organs with amyloid deposits, primarily affecting the heart and…

AbstractPurpose of ReviewCardiac amyloidosis (CA) results from myocardial infiltration by misfolded amyloidogenic proteins and represents a heterogeneous group of…

Join us March 13-15, 2026, for the virtual Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management.Led by Program Chair, Saurabh Malhotra, MD…